ORKA
Oruka Therapeutics, Inc.·Healthcare
57.99
1.812%(−1.07)
Close PriceLast Updated: — ET
52W L: $10.6452W H: $91.00
ORKA NEWS
globenewswire.com
May 13
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
fool.com
May 13
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
prnewswire.com
May 6
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.
defenseworld.net
Apr 29
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing
Oruka Therapeutics (NASDAQ: ORKA) reported 16-week interim results from EVERLAST-A, a double-blind, placebo-controlled phase II study evaluating ORKA-001, the company's extended half-life IL-23/p19 monoclonal antibody for moderate-to-severe plaque psoriasis. Management highlighted what it described as a potentially "category-winning" efficacy profile alongside a safety profile consistent with the IL-23 inhibitor class, and pointed to pharmacokinetic data supporting
globenewswire.com
Apr 28
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In addition, Oruka has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,449,000 shares of Oruka's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Oruka. The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions.
seekingalpha.com
Apr 27
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
